Status:
COMPLETED
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
Lead Sponsor:
Biogen
Conditions:
Progressive Multifocal Leukoencephalopathy
Eligibility:
All Genders
Brief Summary
The primary purpose of this study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) among patients who switched to Tysabri from disease modifying therapies (DMTs), inclu...
Detailed Description
This is an observational cohort study utilising all available data from the Tysabri TOUCH (TYSABRI Outreach: Unified Commitment to Health) prescribing programme (US) supplemented with data from Europe...
Eligibility Criteria
Inclusion
- Key
- All TOUCH and available EU MS registry participants who have switched from DMTs (including fingolimod, dimethyl fumarate, teriflunomide, interferon beta and glatiramer acetate) and have one or more infusion(s) of Tysabri.
- Key
Exclusion
- Not applicable
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
June 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
80327 Patients enrolled
Trial Details
Trial ID
NCT03399981
Start Date
June 1 2017
End Date
December 31 2023
Last Update
March 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Cambridge, Massachusetts, United States, 02142